On this page
Holocarboxylase synthetase deficiency
This condition impacts various metabolic processes, leading to problems such as skin rashes, hair loss, and neurological symptoms. It is caused by genetic changes in the HLCS gene and affects individuals from infancy.
Available at Jeen Health
Clinical tests that include this
Overview
Holocarboxylase synthetase deficiency is a rare genetic condition that affects the body's metabolism. It occurs when there's a problem with an enzyme called holocarboxylase synthetase. This enzyme is crucial for activating several other enzymes, known as biotin-dependent carboxylases, by attaching a vitamin called biotin to them [PMID:10098595]. Without properly working biotin-dependent carboxylases, the body struggles to break down certain fats, proteins, and carbohydrates, leading to a build-up of harmful substances.
This condition is part of a group of disorders known as inherited errors of metabolism (IEM). While it is rare, early diagnosis and treatment can significantly improve outcomes. Symptoms can vary in severity and may appear shortly after birth or later in infancy.
Symptoms & clinical features
The symptoms of holocarboxylase synthetase deficiency can vary, but typically include a range of issues affecting several body systems. In newborns and infants, symptoms may include feeding difficulties, vomiting, lethargy (lack of energy), and hypotonia (poor muscle tone). Skin rashes, often described as scaly or red, are common, particularly around the mouth, eyes, and genital area [PMID:10098595].
Neurological symptoms can also occur, such as seizures and developmental delay. Hair loss (alopecia) is another frequently observed sign. If left untreated, the condition can lead to more severe metabolic crises, affecting breathing and consciousness. Early detection and treatment are important to prevent these serious complications.
Video: Genetics 101
Affected organs
Holocarboxylase synthetase deficiency primarily affects metabolic processes throughout the body, meaning many organ systems can experience secondary effects. The skin is commonly affected, leading to characteristic rashes and hair loss. The nervous system can also be impacted, potentially causing seizures and developmental delays.
Because the condition disrupts the breakdown of fats, proteins, and carbohydrates, it can affect the normal functioning of the liver and other organs involved in metabolism. The immune system may also be weakened, leading to an increased susceptibility to infections.
Risks & severity
The severity of holocarboxylase synthetase deficiency can vary widely among individuals, ranging from mild to severe forms. Without intervention, severe forms can lead to life-threatening complications, especially in early infancy [PMID:10098595]. The age of symptom onset can also differ; some individuals show signs shortly after birth, while others may develop symptoms later in childhood.
Long-term outcomes are closely linked to how early the condition is diagnosed and treated. Prompt and consistent management, primarily involving biotin supplementation, can often prevent or reduce the severity of many symptoms, allowing for more typical development and a better quality of life. Without treatment, there is a risk of significant neurological damage and other serious health problems.
Genetic causes
Holocarboxylase synthetase deficiency is caused by pathogenic variants in the HLCS gene. The HLCS gene provides instructions for making an enzyme called holocarboxylase synthetase. This enzyme has a vital role in activating four specific enzymes known as biotin-dependent carboxylases [PMID:10098595].
Biotin-dependent carboxylases are essential for several metabolic pathways, including the breakdown of certain amino acids (the building blocks of proteins), fatty acids, and the production of glucose. Holocarboxylase synthetase works by attaching a molecule of biotin (vitamin B7) to these carboxylase enzymes, making them functional. When there are pathogenic changes in the HLCS gene, the holocarboxylase synthetase enzyme either doesn't work correctly or isn't produced in sufficient amounts, preventing the biotin-dependent carboxylases from becoming active. This disruption leads to the metabolic imbalances observed in the condition.
- HLCS holocarboxylase synthetaseThe HLCS gene provides instructions for producing holocarboxylase synthetase, an enzyme vital for activating biotin-dependent carboxylases involved in key metabolic processes.
Inheritance pattern
Holocarboxylase synthetase deficiency has an autosomal recessive inheritance pattern. This means that a child must inherit two copies of the altered HLCS gene, one from each parent, to develop the condition.
Individuals who inherit only one copy of the altered gene are known as carriers. Carriers typically do not show symptoms of the condition themselves because their single functional copy of the gene is usually sufficient to produce enough active holocarboxylase synthetase. If both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two altered copies of the gene and develop the condition, a 50% chance the child will be a carrier, and a 25% chance the child will not inherit any altered genes.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of holocarboxylase synthetase deficiency typically begins with clinical suspicion based on an individual's symptoms. Newborn screening programmes in some regions may include tests that can identify this condition or indicators of it, allowing for very early diagnosis. If the condition is suspected, biochemical tests can be performed to look for characteristic metabolic abnormalities in blood and urine samples, such as elevated levels of certain organic acids.
A definitive diagnosis is confirmed through genetic testing, which looks for pathogenic variants in the HLCS gene. In the UK, genetic testing for inherited metabolic disorders is available through the NHS Genomic Medicine Service (GMS). Referral for genetic testing would typically be made by a specialist paediatrician or metabolic consultant, often following an R-code pathway. Clinical geneticists and genetic counsellors can provide further information and support throughout the diagnostic process.
Management & lifestyle
The primary management for holocarboxylase synthetase deficiency involves lifelong supplementation with biotin. High doses of biotin are often effective in activating the remaining functional holocarboxylase synthetase or in providing enough biotin to overcome the enzyme's reduced efficiency [PMID:8192667]. Early initiation of biotin therapy, ideally before the onset of significant symptoms, is crucial for preventing severe complications and improving long-term outcomes.
Management also includes regular monitoring by a metabolic specialist, typically through an NHS metabolic unit. This involves monitoring biochemical markers and assessing neurological development and overall health. A multidisciplinary team, which may include paediatricians, neurologists, dietitians, and genetic counsellors, often supports individuals with this condition. While biotin supplementation is highly effective for most individuals, specific management plans are tailored to each person's needs and response to treatment.
UK care pathway
In the UK, individuals suspected of having an inherited metabolic disorder such as holocarboxylase synthetase deficiency would typically be referred to a specialist metabolic centre, usually within a paediatric setting for children. The NHS Genomic Medicine Service (GMS) provides access to genetic testing for rare and inherited diseases, which includes the HLCS gene (often part of a broader R-code panel for metabolic conditions). Referrals are often made by general practitioners or other specialists to clinical genetics services or directly to metabolic teams.
Genetic counsellors play a key role in explaining the condition, its inheritance pattern, and the implications for the family. They can also provide support and discuss testing options for family members. The care pathway emphasises a coordinated approach to diagnosis and management within the NHS.
Frequently asked questions
What is biotin and why is it important for this condition?
Biotin is a B vitamin (vitamin B7) that acts as a coenzyme, meaning it helps other enzymes work properly. In holocarboxylase synthetase deficiency, biotin cannot be properly attached to specific metabolic enzymes, which are vital for breaking down fats, proteins, and carbohydrates. Supplementing with high doses of biotin can often overcome this issue.
Will my child's symptoms improve with treatment?
For many individuals, especially when treatment begins early, symptoms can significantly improve with biotin supplementation. Skin rashes often clear, hair can regrow, and neurological development may progress more typically. Lifelong treatment and regular monitoring are usually needed to maintain good health.
Is holocarboxylase synthetase deficiency picked up by newborn screening?
Newborn screening programmes vary by region within the UK and internationally. While some programmes may detect indicators of this condition, it is not universally included in all standard newborn screening panels. If it is not detected by screening, symptoms may prompt a later diagnosis.
What does 'autosomal recessive inheritance' mean for my family?
Autosomal recessive inheritance means that both parents must be carriers of a pathogenic change in the HLCS gene for their child to inherit the condition. If you have one child with the condition, there is a 1 in 4 chance (25%) with each subsequent pregnancy that another child will also have it. Genetic counselling can provide detailed information and support for your family.
Are there any dietary restrictions for someone with this condition?
Typically, there are no specific dietary restrictions required for individuals with holocarboxylase synthetase deficiency, especially once they are on effective biotin supplementation. The main focus is on ensuring consistent biotin intake. However, a dietitian may be involved to monitor overall nutrition and growth, particularly in infancy.
References
- Karachaliou CE, Livaniou E. Biotin Homeostasis and Human Disorders: Recent Findings and Perspectives. International journal of molecular sciences. 2024. PMID: 38928282
- Bandaralage SP, Farnaghi S, Dulhunty JM. Antenatal and postnatal radiologic diagnosis of holocarboxylase synthetase deficiency: a systematic review. Pediatric radiology. 2016. PMID: 26754537
- Donti TR, Blackburn PR, Atwal PS. Holocarboxylase synthetase deficiency pre and post newborn screening. Molecular genetics and metabolism reports. 2016. PMID: 27114915
- Daley SF, Shah M. Newborn Screening. 2026. PMID: 32644409
- ZeZhao J, Ablimit A. Holocarboxylase synthetase deficiency: pathogenesis, clinical features, diagnosis, treatment, and research prospects. European journal of pediatrics. 2026. PMID: 42324336
- Ling S, Qiu W, Zhang H. Clinical, biochemical, and genetic analysis of 28 Chinese patients with holocarboxylase synthetase deficiency. Orphanet journal of rare diseases. 2023. PMID: 36890565
- Gibson KM, Bennett MJ, Nyhan WL. Late-onset holocarboxylase synthetase deficiency. Journal of inherited metabolic disease. 1996. PMID: 8982946
- Tammachote R, Janklat S, Tongkobpetch S. Holocarboxylase synthetase deficiency: novel clinical and molecular findings. Clinical genetics. 2010. PMID: 20095979